Dr. Bradley Rosen out of Los Angeles, who prescribes rapamycin, talks with Dr. Robert Lufkin about how he looks at risk in aging, and his view of therapeutics like rapamcyin and acarbose:
We have seen this chart before. Every study I have read regarding rapamycin dosage and lifespan indicates higher doses result in a longer lifespan.
Sorry, this chart has been posted before.
Great! Have Bradley shared any were if he is taking rapamycin himself?
I’ve not heard - but the way he talks, I strongly suspect he’s taking rapamycin.
He’s on twitter - you might message him and see if he responds:
What is the difference between the red, purple and green lines??? Are they just guesses? It could go up a lot, go up a little or go down???
Yes - but those were estimates in 2014. We know a lot more now.
They’ve done doses up to the equivalent of 378ppm now in mice (for a few months) and had good results (with the male mice), and have not found an upper limit in terms of most effective dose (at least for males). I think they did find a peak dose for female mice at 108ppm I think… details here:
42ppm in the ITP studies.
There is a theory that Acarbose works because it stops carbohydrate being digested. The carbohydrate then travels further along the bowel where it is broken down by bacteria, which produce gas. This creates the excessive flatulence noted by those who use acarbose.
But an “extension” to the theory is that at least some of the gas produced is hydrogen and that longevity benefits ascribed to acarbose are, in fact, due to hydrogen.
I like that theory. BTW I am going to make hydrogen-enriched water and drink 500ml/day and see what if any effects it has on my biomarkers.